Robert Steyer

Special to TheStreet.com

Robert Steyer, who joined TheStreet.com in July 2003, has written about the business of science, medicine and health care for the St. Louis Post-Dispatch and the Newark Star-Ledger. He also has been a reporter for Fortune, an editor at CFO Magazine and an assistant business editor at the Tampa Tribune.

He has a B.A. in government from Oberlin College and an M.B.A. from New York University.

Robert Steyer
By This Author:
« Back
Page 1 of 147
Article

Baxter International Hiding in Plain Sight

By Robert Steyer

In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?

Related Topics: Health Care | Drugs

06:59AM 07/01/08

Article

Generic-Drug Stocks Still Under the Weather

By Robert Steyer

Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.

Related Topics: Health Care | Drugs

01:40PM 06/05/08

Article

Need Defense? Think Medical Supplies

By Robert Steyer

Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.

Related Topics: Health Care | Stock Picks

06:44AM 04/11/08

Article

The Real Winners of Drug Experimentation

By Robert Steyer

The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.

Related Topics: Health Care | Drugs | Biotech

06:59AM 04/03/08

Article

A Safer Way to Play the Drug Sector

By Robert Steyer

Contract research organizations aren't without risks of course, but they do offer some protection against the vagaries of the industry.

Related Topics: Drugs | Health Care

06:16AM 02/26/08

Article

Schering-Plough's Adjusted Profits Top Estimates

By Robert Steyer

Shares rise 5.4% on the news.

Related Topics: Health Care | Drugs

02:56PM 02/12/08

Article

Reasons to Believe in Schering-Plough

By Robert Steyer

Despite the Vytorin setback, the focus here should be on drugs in development, not products in the market.

Related Topics: Stock Picks | Health Care | Drugs

02:05PM 02/11/08

Article

Big Pharma Moving More Work Offshore

By Robert Steyer

Merck, Pfizer and others are getting used to a new world that requires cost discipline.

Related Topics: Drugs | Health Care

02:06PM 01/25/08

Article

Are IPOs Poised for Another Banner Year?

By Robert Steyer

If a recession can be avoided, 2008, like last year, could be active for initial issues.

Related Topics: Markets

11:07AM 01/21/08

Article

Big Pharma Considers Kicking the OTC Habit

By Robert Steyer

Several firms are debating whether to bulk up or shed lower-margin units.

Related Topics: Drugs | Health Care

06:14AM 12/18/07

« Back
Page 1 of 147
Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now.

Keep on top of the market and the critical information you need to make more profitable investing decisions.

  • Cramer's Daily Booyah!
  • Before the Bell

Privacy Policy

See All Free Newsletters

Premium Stock Ideas